Influenza Treatment in Children
Introduction to Influenza Treatment
- The American Academy of Pediatrics does not recommend the use of antiflu formulations containing amantadine, chlorphenamine, and paracetamol in children due to safety concerns, limited efficacy against current influenza strains, and potential for adverse effects 1, 2
- Annual influenza vaccination remains the primary strategy for prevention, according to the CDC and the ACIP 3, 4
Active Ingredients and Concerns
- Amantadine is only effective against influenza A viruses, not influenza B, and has high rates of viral resistance development, according to the CDC 1, 2
- Amantadine carries a risk of central nervous system side effects, particularly in pediatric patients, according to the American Academy of Pediatrics 5
- The FDA-approved dosage for children aged 1-9 years is 4.4-8.8 mg/kg/day, not to exceed 150 mg/day, as recommended by the American Academy of Pediatrics 1
Preferred Treatment Approach
- Neuraminidase inhibitors (oseltamivir or zanamivir) are the preferred antiviral agents for pediatric influenza management, as recommended by the American Academy of Pediatrics 6, 3
- Oseltamivir is approved for treatment in children ≥1 year, while zanamivir is approved for treatment in children ≥7 years, according to the American Academy of Pediatrics 6, 3
- Neuraminidase inhibitors have several advantages, including:
Treatment and Monitoring
- Treatment with neuraminidase inhibitors should be started within 48 hours of symptom onset, as recommended by the American Academy of Pediatrics 6, 3, 9
- Monitor for signs of adverse effects, particularly CNS symptoms with amantadine, according to the American Academy of Pediatrics 5
- Duration of treatment is typically 5 days for neuraminidase inhibitors 3
- High-risk children should receive prompt antiviral treatment when influenza is suspected, even if more than 48 hours have passed since symptom onset 7